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Abstract: Background: Scientific evidence on the effect of health insurance on racial disparities in
urinary bladder cancer patients’ survival is scant. The objective of our study was to determine
whether insurance status modifies the association between race and bladder cancer specific survival
during 2007–2015. Methods: The 2015 database of the cancer surveillance program of the National
Cancer Institute (n = 39,587) was used. The independent variable was race (White, Black and Asian
Pacific Islanders (API)), the main outcome was cancer specific survival. Health insurance was divided
into uninsured, any Medicaid and insured. An adjusted model with an interaction term for race
and insurance status was computed. Unadjusted and adjusted Cox regression analysis were applied.
Results: Health insurance was a statistically significant effect modifier of the association between race
and survival. Whereas, API had a lower hazard of death among the patients with Medicaid insurance
(HR 0.67; 95% CI 0.48–0.94 compared with White patients, no differences in survival was found
between Black and White urinary bladder carcinoma patients (HR 1.24; 95% CI 0.95–1.61). This may
be due a lack of power. Among the insured study participants, Blacks were 1.46 times more likely
than Whites to die of bladder cancer during the 5-year follow-up (95% CI 1.30–1.64). Conclusions:
While race is accepted as a poor prognostic factor in the mortality from bladder cancer, insurance
status can help to explain some of the survival differences across races.
Keywords: carcinoma; transitional cell; mortality; survival rate; urinary bladder neoplasms
1. Introduction
The American Cancer Society estimated that in 2018 there will be 81,190 new cases of bladder
cancer with an estimated number of new deaths projected to be 17,240, making it the fifth most common
cause of cancer in the U.S. [1]. From the years 1989 to 2013, the five year survival have remained
relatively stable [1].
The current scientific evidence on the association between race and overall survival of patients
with bladder cancer consistently reports a disparity between blacks and Whites [1–14]. Retrospective
Int. J. Environ. Res. Public Health 2019, 16, 3393; doi:10.3390/ijerph16183393 www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2019, 16, 3393 2 of 10
cohort studies using data from the Surveillance, Epidemiology, and End Results Program (SEER)
database and National Cancer Databases (NCDB) have found that the five year overall survival from
bladder cancer in Blacks was significantly lower than the overall survival of Whites during the last
three decades [2–4,8,15].
Whereas most of the previous studies controlled their statistical models for marital status, gender,
tumor-related characteristics types of surgeries, other clinical factors, only very few of them tried to
assess the associations between health insurance or whether the association between race and survival
depends on the health insurance of the patients [6,12]. Given that in 2017, the census bureau found
that of a total of 323,156 participants 9% of the population was uninsured (n = 28,543), information
on survival according to health insurance in urinary bladder cancer patients may help to address
the needs of the most vulnerable population groups [16]. Finally, information in regard association
between race, insurance and survival in Asian/Pacific Islanders is scant.
Therefore, the aim of this study was to determine whether insurance status modifies the association
between race and bladder cancer-specific survival in patients with urinary bladder malignancy in the
U.S. We hypothesize that race as a prognostic factor for 5-year bladder cancer specific survival behaves
differently depending on the insurance status of the patient.
2. Materials and Methods
2.1. Study Design and Setting
A secondary data analysis of the Surveillance Epidemiology and End Results (SEER 9) database was
conducted. SEER is a cancer surveillance program of the National Cancer Institute’s (NCI) that collects
cancer incidence and survival data since 1973, including the Atlanta, Detroit, San Francisco Oakland,
Seattle-Puget Sound metropolitan areas and the states of Connecticut, Hawaii, Iowa, New Mexico, and
Utah [17].
2.2. Study Participants
The population of interest included adults 18 years-of-age or older, identified as White, Black, and
Asian Pacific Islander (API) with a first-time diagnosis of urinary bladder malignancy (International
Classification of Diseases for Oncology, 3rd Edition [ICD-O-3], codes C67.0-C67.9, and histology code
8120-8130 from 2007 to 2015 (n = 39,587). Thus, the study population was restricted to first primary
and histologically confirmed cases. The period of this study was chosen due to the SEER 9 database
beginning to record insurance status in 2007. Cases with missing data on race (n = 504), unknown cause
of death or missing information on survival (n = 1071), confirmed or possible diagnosis at autopsy
(n = 171) or duplicate cases (n = 176) were excluded. For the rest of the variables in the study, the
percentage of missing was less than 8% (status: 7.97%, insurance: 5.30%, stage: 1.23%, surgery: 0.18%).
The final population consisted of 37,871 patients.
2.3. Main Variables
The primary outcome was five-year cause-specific mortality which was defined as the time in
months from diagnosis to death due to cancer specific causes. Patients who were alive at the date of
the last contact (60 months after diagnosis) were censored. Race was defined as White, Black, and
API. Healthcare coverage in the U.S. is provided through a combination of private health insurance
and public health coverage such as Medicaid. It has been estimated that close to 91% percent of the
U.S. population had some type of health insurance. Most Americans with private health insurance
receive it through an employer-sponsored program. Medicaid in the United States is a federal and state
program that helps with medical costs for some people with limited income and resources. People
who do not have a health-insurance (the uninsured) have to pay for their health services. In this study,
health insurance status was grouped into uninsured, any Medicaid and Insured (combining SEER
Insured and Insured/No specifics categories). SEER report insurance status of the patient based on the
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primary payer at diagnosis according to NAACCR Field Primary Payer at diagnosis. SEER does not
provide much detail about the services covered by Medicaid or other insurances.
Other covariates included age at diagnosis, gender, ethnicity, marital status, grade at diagnosis,
stage at diagnosis, and surgical treatment. Age in years was divided into the following categories
<50, 50–59, 60–69, 70–79, 80–89, 90+ years-of-age. Ethnicity was dichotomized into Hispanic or
non-Hispanic. Marital status was defined as partnered (married, and unmarried/domestic partner)
and un-partnered (single, separated, divorced, and widowed). Grade at diagnosis was categorized in
four groups: (1) well or moderately differentiated, (2) poorly differentiated, (3) undifferentiated, and
(4) ungraded. Stage at diagnosis categories was defined as localized, regional, and distant; patients
that were un-staged at diagnosis were excluded. Surgical treatment was dichotomized into surgical
treatment not performed or performed (this category included codes for local tumor destruction
not otherwise specified (NOS), local tumor excision NOS, electrocautery, excisional biopsy (TURB),
complete cystectomy with reconstruction, radical cystectomy plus ileac conduit, radical cystectomy
including anterior exenteration.
2.4. Statistical Methods
Statistical analysis was performed using STATA (StataCorp LP., College Station, TX, USA) [18].
Categorical variables are presented as proportions. Chi-square tests were used to compare categorical
covariates according to the exposure and outcome variables. Kaplan-Meier survival analysis was
used to compare overall survival curves. The log-rank test was used to assess differences between
survival curves across race/ethnicity. Collinearity was assessed via pairwise correlations. A Pearson’s
correlation coefficient absolute value of 0.67 or higher was used for identifying collinearity among a
pair of variables. In the study, no collinearity was found among any of the variables included. Patients
were follow-up for a maximum length of five years. Unadjusted and adjusted Cox Proportional hazard
regression models were used to calculate hazard ratios (HRs) and their corresponding 95% confidence
intervals (CIs). Age at diagnosis, gender, marital status at diagnosis, grade at diagnosis, stage at
diagnosis, and surgical treatment were included in the adjusted model. Wald test was performed for
each variable in order to test the statistical significance of each variable in the model. The adjusted
model with an interaction term for race and insurance status was fitted. As at least one of the interaction
terms of race*insurance was statistically significant, showing possible effect modification by health
insurance, the adjusted model was stratified for each stratum of health insurance. The proportional
hazard assumptions were tested graphically. All p values reported are two-tailed, and a p-value of <0.05
was considered as statistically significant.
2.5. Ethical Considerations
Permission to use and access to the SEER database was obtained through the SEER website.
All data accessed from SEER was de-identified (fully anonymized) and without any of the 18 direct
identifiers according to the Health Insurance Portability and Accountability Act. Ethical approval was
waived by the Florida International University Health Sciences IRB since the analysis was considered
nonhuman subjects research using de-identified data.
3. Results
Table 1 describes the demographic and baseline clinical characteristics of the study participants
diagnosed with bladder cancer in the SEER database between 2007 and 2015. Across all races, a higher
proportion of patients were diagnosed with bladder cancer between the ages of 60–69 years (White 28%,
Black 31.2%, API 26.2%) and 70–79 years (White 28.8%, Black 22.5%, API 28.2%). Furthermore,
a higher proportion of Blacks were diagnosed with bladder cancer at a younger age (<50, 50–59,
60–69) compared with Whites and API. Blacks also had a higher frequency of being females (32.7%),
unpartnered (58.7%), and being either uninsured (3.7%) or having Medicaid (13.0%) compared with
Whites and API. Regional (22.2%) or distant (7.03%) cancer bladder cancer stage as well as higher
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grading of the disease were more prevalent in Blacks than in the Whites and API study population.
Blacks also had a lower prevalence of patients who underwent surgery (91.1%) than Whites and API.
All of these differences in demographic and clinical characteristics between the race groups were found
to be statistically significant (p-values < 0.001).
Table 1. Baseline characteristics of study participants with primary urinary bladder cancer according
to race during 2007–2015.
Characteristics
Race
p-Value 2White
(N = 33,876)
Black
(N = 2005)
API 1
(N = 1990)
% % %
Age (years) <0.001
<50 4.78 7.73 4.37
50–59 14.3 20.85 13.57
60–69 27.95 31.22 26.18
70–79 28.75 22.54 28.19
80–89 20.51 14.71 22.76
90+ 3.21 2.94 4.92
Gender <0.001
Male 77.31 67.28 74.87
Female 22.69 32.72 25.13
Ethnicity <0.001
Non-Hispanic 96.57 99.2 98.49
Hispanic 4.43 0.8 1.51
Marital status <0.001
Partnered 64.93 41.31 68.78
Unpartnered 35.05 56.69 31.22
Insurance status <0.001
Uninsured 1.47 3.68 1.58
Any Medicaid 5.52 13.02 15.05
Insurance 93.02 83.3 83.37
Stage <0.001
Localized 79.78 70.82 77.82
Regional 16.92 22.15 18.7
Distant 3.3 7.03 3.47
Grade <0.001
Grade I/II 32.98 24.44 33.07
Grade III 13.24 15.62 11.61
Grade IV 34.06 38.65 41.46
Not Graded 19.72 21.75 13.87
Surgery <0.001
Surgery 94.52 91.05 95.09
No Surgery 5.48 0.95 4.91
1 Asian/Pacific Islanders; 2 Chi-square test.
Figures 1–3 show the Kaplan Meier curves for cancer specific survival in months according to
health insurance. The log-rank test revealed a statistically significant difference in survival among the
different races in the insured patients and those with Medicaid (p-values < 0.001). Black had lower
survival compared with White or API in both health insurance groups. However, no differences in
survival was found between White, Black or API uninsured patients (Figure 3; p-value = 0.429).
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The range of f llow up was betwe n 0 a d 60 months. Median survival time could not be computed
since mor tha 50% of individuals were alive at th end of follow up. The mean survival time for the
sample was 52.6 onths. Table 2 presents the adjusted hazard ratios for cause-specific 5-year survival
with the interaction term Race*Insurance included. The interaction term API & Any Medicaid was
statistically significant suggesting possible interaction between health-insurance and survival.
Table 2. Adjusted hazard ratios for cause-specific 5-year survival stratified by insurance status among
adult patients diagnosed with bladder cancer (SEER 2007–2015).
Characteristics
Adjusted Estimates
i s red edicaid Insured
(n = 571) Wald Test
p-Values
(n = 2304) Wald Test
p-Values
(n = 32,988) ald Test
p-ValuesHR a (95% CI b) HR (95% CI) HR (95% CI)
Race 0.471 0.013 <0.001
White Ref. c Ref. Ref.
Black 1.19 (0.58–2.42) 1.24 (0.95–1.61) 1.46 (1.30–1.64)
API d 0.44 (0.10–1.89) 0.67 (0.48–0.94) 0.99 (0.86–1.14)
Age (years) 0.002 0. 01 < .001
<50 Ref. f. Ref.
50–59 1. ( . 2.70) . (0.83–1.85) 1.22 (0.97–1. 5)
60–69 1.19 (0.54–2.62) 1.18 (0.80–1.75) 1.50 (1.20–1.87)
70–79 1.42 (0.45–4.49) 1.48 (0.98–2.22) 2.03 (1.63–2.53)
80–89 2.06 (0.59–7.22) 2.29 (1.50–3.49) 3.52 (2.83–4.38)
90+ 17.40 (4.28–70.65) 2.61 (1.29–5.29) 6.52 (5.13–8.27)
Gender 0.888 0.176 0.058
Male Ref. ef. Ref.
Female 1.04 (0.59–1.83) 1.16 (0.94–1.44) 1.07 (1.00–1.15)
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Table 2. Cont.
Characteristics
Adjusted Estimates
Uninsured Medicaid Insured
(n = 571) Wald Test
p-Values
(n = 2304) Wald Test
p-Values
(n = 32,988) Wald Test
p-ValuesHR a (95% CI b) HR (95% CI) HR (95% CI)
Ethnicity 0.936 0.027 0.025
Non-Hispanic Ref. Ref. Ref.
Hispanic 1.03 (0.42–2.53) 0.68 (0.49–0.96) 1.21 (1.02–1.43)
Marital Status 0.966 0.121 <0.001
Partnered Ref. Ref. Ref.
Unpartnered 0.99 (0.62-1.59) 1.19 (0.96–1.48) 1.29 (1.21–1.38)
Stage <0.001 <0.001 <0.001
Localized Ref. Ref. Ref.
Regional 5.08 (2.73–9.44) 5.05 (3.89–6.55) 6.57 (6.08–7.09)
Distant 18.54 (9.02–38.11) 18.24(13.54–24.55)
26.75
(24.20–29.56)
Grade 0.001 <0.001 <0.001
Grade I/II Ref. Ref. Ref.
Grade III 10.57 (2.92–38.28) 4.31 (2.68–6.94) 3.14 (2.74–3.59)
Grade IV 6.90 (1.97–24.15) 3.73 (2.37–5.86) 3.01 (2.65–3.42)
Not Graded 2.83 (0.73–10.90) 2.24 (1.34–3.66) 1.90 (1.64–2.20)
Surgery 0.013 <0.001 <0.001
Surgery Ref. Ref. Ref.
No Surgery 3.08 (1.27–7.47) 2.02 (1.44–2.83) 1.90 (1.67–2.17)
a Hazard ratio; b Confidence interval; c Reference group; d Asian/Pacific islander.
The interaction of race*insurance was statistically significant in the adjusted logistic regression
models revealing possible effect modification by health insurance (data not shown). Therefore,
the adjusted model was stratified according to health insurance. The adjusted hazard ratios for
cancer-specific survival stratified by insurance are shown in Table 2. There was no statistically
significant association between race and survival between White, Blacks, API urinary bladder cancer
patients that were uninsured (HR for Black 1.19 [95% CI 0.58–2.42); HR for API 0.44 [95% CI 0.10–1.89]).
Whereas, API had a lower hazard of death among the patients with Medicaid insurance (HR 0.67;
95% CI 0.48–0.94 compared with White patients, no differences in survival was found between Black
and White urinary bladder carcinoma patients (HR 1.24; 95% CI 0.95–1.61). Among the insured
study participants, Blacks were 1.46 times more likely than Whites to die of bladder cancer during
the 5-year follow-up (95% CI 1.30–1.64). However, insured API had the same survival than their
White counterparts (HR 0.99; 95% CI 0.86–1.14). As the most important secondary finding, it may
be noteworthy to mention that among the insured patients, Hispanics were more likely to die from
bladder cancer than non-Hispanics (HR 1.21; 95% CI 1.02–1.43).
4. Discussion
Our study showed that the association between race and 5-year survival in bladder cancer
patients depended on insurance status. Black patients who were insured had a higher hazard of death
compared with their White counterparts, whereas being API, the survival is better in the Medicaid
patient group. Hispanic patients with health insurance had a higher hazard of death compared with
non-Hispanics. Finally, the post-hoc power calculations and small sample size of the uninsured in the
sample revealed a low power to detect a statistically significant results when comparing Black or API
with White individuals among uninsured patients. Thus, one of the reasons why our data did not
reveal a statistically significant associations between race and survival among the Black uninsured
patients and those with Medicaid may be due to lack of power.
Our findings revealed that the association between race and survival depends on the insurance
status of the patient. Our data is in line with the previous scientific evidence [6,12]. Mallin et al. reported
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that bladder transitional cell carcinoma patients who were either uninsured or had Medicaid—were at
50%, respectively 70% increased risks of death compared with patients who were privately insured [6].
A study examining the association between health insurance status and survival of New Jersey
patients 18–64 diagnosed with seven common cancers during 1999–2004 found that uninsured
bladder cancer patients had statistically significantly lower survival rates than privately insured
patients [12]. Uninsured patients were 76% more likely to die from bladder cancer compared to
insured patients, respectively [12]. On contrast to our study, previous ones did not report findings
including API. A retrospective analysis of the cancer stage at diagnosis for 12 cancer sites in the USA,
diagnosed between 1998 and 2004 using the US National Cancer Database reported that uninsured and
Medicaid-insured patients are at least twice as likely to present with regional disease and 60% more
likely to have locally-advanced disease at diagnosis compared with privately insured patients [10,13].
A possible non-biological explanation for the survival disparity according to health insurance is the
documented inequality Blacks face in access to quality care. Blacks who are insured may be restricted
to community-based healthcare systems that may not have the experience or infrastructure to care
for complex conditions [10,19,20]. Other factors such as transportation, affordability, and distrust of
the healthcare system have historically hindered Blacks from receiving timely care [10,21]. Insurance
status is not the only factor that contributes to a patient’s access to care. Transportation, willingness to
seek medical care, attitudes toward healthcare providers among other factors may also play a role [10].
Our data is in agreement with most of the few previous studies assessing survival in urinary
bladder cancer patients according to race [3,5–7,22]. A study in U.S. urinary bladder cancer patients
using data from SEER during 1973 and 2014 found that Non-Hispanic Whites had the best survival rates
during a five-year follow-up [7]. Moreover, they also reported that Blacks had a statistically significant
lower survival than other racial groups even when controlling for gender, age, histology, tumor size
and surgical treatment [7]. Another study following-up patients diagnosed with transitional cell
carcinoma of the bladder between 1975 and 2005, reported that cancer-specific survival was reduced in
blacks compared with other ethnic groups, even when stratified by stage and grade [3]. Also, data from
the Florida Cancer Data System and the Agency for Health Care Administration data sets (1998–2003)
revealed a statistically significantly longer survival in Whites (63.0 months) compared with Blacks
(39.6 months) [5]. However, a recent analysis of overall survival and bladder cancer-specific survival
in patients with metastatic bladder cancer using the SEER 2010–2013 data did not find any statistically
significant differences in survival between Whites and Blacks [22]. Moreover, an analysis of bladder
transitional cell carcinoma cases diagnosed in 1993 to 2007 from the National Cancer Data Base found
that the 30% higher mortality risk in black males and females was primarily limited to late stage
diseases [6].
Several factors may explain why Blacks have a decreased survival compared with White bladder
cancer patients. Possible explanations for this disparity are differences in the smoking prevalence,
comorbid conditions, type and quality of care, genetics and socioeconomic status between Blacks and
Whites [6,9,10,20]. It has also been suggested that the racial difference in cancer-specific survival may
be due to the advance stage of disease at time of diagnostics [6,9,10]. Gild et al. found a difference in
length of time to neoadjuvant chemotherapy and radical cystectomy, amount of lymph nodes removed,
length of stay in days, neoadjuvant chemotherapy utilization, and pelvic lymph node dissection
between Blacks and Whites [4]. They concluded that Black patients with muscle invasive bladder
cancer undergoing radical cystectomy and possible neoadjuvant chemotherapy may receive a lower
quality of care than White patients. Finally, factors related to health-care provider or accessing to
medical care or differential treatment of patients by race may play an important role in explaining the
existing health disparity between Blacks and Whites. Thus, further studies may explore in more depth
socioeconomic barriers such as income, factors related to health education or medical depths between
different race to access health-care and proper treatment and surveillance [23].
Naturally, our study had some limitations. The SEER database does not record detailed information
about significant lifestyle habits such as smoking status, occupational exposures and educational status.
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Also, information on genetic factors were not available. Thus, these factors may over or underestimate
the strength of the association between race, health insurance and survival. Moreover, SEER assumes
all patients age > 65 years have Medicare, but codes them as insured, making it impossible to further
stratify insurance status from public or private sources which we feel could have highlighted further
disparities. Furthermore, it was not possible to identify the primary site of care of patients, thus access
to appropriate care could have affected our findings. Finally, we were also limited in the information
available about surgical treatments performed since only the initial surgical procedure was recorded
rather than the most definitive treatment, making it impossible to delineate differences in level of care
received (e.g., number of lymph nodes sampled, surgical procedures performed/offered or skills of
the surgeons).
5. Conclusions
In conclusion, our results indicated that while race is largely accepted as a poor prognostic factor in
bladder cancer specific survival, insurance status can help to explain some of the prognostic differences
across races, though it does not fully elucidate the cause of the disparity. Differences in mortality
from bladder cancer is multifactorial and is associated with quality of care and access to treatment.
This may mean that in addition to the biologic differences between races, insurance status plays a
pivotal role in the cancer survival. In light of these results, we suggest to include interventions for
clinicians to identify high risk patient populations and connecting them with additional services such
as educational materials, case management, transportation services, and identification of other social
determinants of health that impede access to quality care. Future efforts should be made to further
explore the variation in access to care, quality of care, and institutional availability for patients of
varying insurance status to improve health outcomes and minimize disparities in cancer survival
between races for patients with bladder cancer.
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